BioSpace News Archive

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced participation in the following investor conferences in May:

Abiomed announces the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery as part of the heart pump’s U.S. Food and Drug Administration Early Feasibility Study.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2022 financial results after market close on Tuesday, May 3, 2022.

Alercell, announced today that it will begin distributing a Leukemia Fusion Gene Screening and Genotyping Kit created and manufactured by Zeesan, a longtime partner of Alercell.

Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis’ ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of Evaxion’s personalized cancer immunotherapy EVX-01.

Vectorious Medical Technologies Ltd., today announced that it has enrolled the first six patients in the VECTOR-HF II Study, which will evaluate the V-LAP System’s novel approach of patient self-management for detecting and managing heart failure (HF) early, before it further damages the heart.

Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), announced today that it has commenced dose administration of the first subject in a Phase I/IIa clinical trial of the Company’s novel drug candidate BMND01, for treatment-resistant depression with inhaled administration.

Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it will present new data from the Phase 3 AMPOWER Clinical Trial at the 2022 American College of Obstetricians and Gynecologists (ACOG) annual meeting.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease designation to EDIT-301, an investigational, gene-edited medicine for the treatment of beta thalassemia.

Harvard Bioscience, Inc. has introduced SmartStudy™, an innovative technology feature to its Buxco® Inhalation System aimed at supporting more precise results, cost savings, and improved productivity for preclinical researchers.